PPCB vs ZTS · P/E 0.0, $3.9M cap vs P/E 25, rev $2.47B
Propanc Biopharma, Inc. Common Stock (PPCB) versus Zoetis Inc (ZTS) — a side-by-side from cached financials, not a winner call.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
PPCB does not have a complete income-statement cache yet.
Latest reported ZTS revenue for 2026-06-30 was $2.47B. Net income was $691.0M. Revenue was up 9.1% from 2026-03-31 to 2026-06-30. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
PPCB currently screens at market cap $3.9M and trailing P/E 0.0. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
Not investment advice. Open the PPCB and ZTS stock pages for the full models.
Not investment advice.